0QNA Stock Overview
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 2/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Basilea Pharmaceutica AG Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CHF37.65 |
52 Week High | CHF50.60 |
52 Week Low | CHF32.20 |
Beta | 0.56 |
1 Month Change | 4.67% |
3 Month Change | 5.02% |
1 Year Change | -25.19% |
3 Year Change | -20.50% |
5 Year Change | -20.13% |
Change since IPO | -68.23% |
Recent News & Updates
Recent updates
Shareholder Returns
0QNA | GB Biotechs | GB Market | |
---|---|---|---|
7D | 5.2% | -1.6% | 0.9% |
1Y | -25.2% | -28.9% | 2.2% |
Return vs Industry: 0QNA exceeded the UK Biotechs industry which returned -27.3% over the past year.
Return vs Market: 0QNA underperformed the UK Market which returned 2.7% over the past year.
Price Volatility
0QNA volatility | |
---|---|
0QNA Average Weekly Movement | 5.4% |
Biotechs Industry Average Movement | 7.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0QNA has not had significant price volatility in the past 3 months.
Volatility Over Time: 0QNA's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2000 | 147 | David Veitch | https://www.basilea.com |
Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union. It also offers medicine drug for invasive fungal infections.
Basilea Pharmaceutica AG Fundamentals Summary
0QNA fundamental statistics | |
---|---|
Market cap | CHF451.92m |
Earnings (TTM) | CHF10.45m |
Revenue (TTM) | CHF157.63m |
43.2x
P/E Ratio2.9x
P/S RatioIs 0QNA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0QNA income statement (TTM) | |
---|---|
Revenue | CHF157.63m |
Cost of Revenue | CHF104.65m |
Gross Profit | CHF52.99m |
Other Expenses | CHF42.54m |
Earnings | CHF10.45m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | 0.87 |
Gross Margin | 33.61% |
Net Profit Margin | 6.63% |
Debt/Equity Ratio | -1,108.7% |
How did 0QNA perform over the long term?
See historical performance and comparison